Welcome to our dedicated page for BIONXT SOLUTIONS news (Ticker: BNXTF), a resource for investors and traders seeking the latest updates and insights on BIONXT SOLUTIONS stock.
BioNxt Solutions Inc. is a bioscience accelerator specializing in next-generation drug formulations, delivery systems, and diagnostic tests for various medical applications. The company has successfully completed toxicity and pharmacokinetic studies for its proprietary Cladribine product aimed at treating Multiple Sclerosis. With a focus on regulatory approval and commercialization in European markets, BioNxt is at the forefront of developing innovative medical products.
Recent achievements include finalizing a settlement agreement with a creditor, advancing to human comparative bioavailability studies, and launching a non-brokered private placement to fund research and development efforts. With a strong emphasis on innovation and collaboration, BioNxt is poised for continued growth and success in the pharmaceutical industry.
Rhea-AI Summary
BioNxt Solutions Inc. (BNXT) Announces Completion of Toxicity Study for Cladribine Product for Multiple Sclerosis Treatment and Non-Brokered Private Placement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.81%
Tags
-
Rhea-AI Summary
BioNxt Solutions Inc. (CSE:NXT)(OTCQB:BNXTF)(FSE:BXT) has received state-of-the-art coating and cutting equipment for commercial manufacturing capacity at its Vektor Pharma TF GmbH facility in Germany. The equipment is designed for the manufacture of oral dissolvable and transdermal drug formulation products. The company is focused on expedited development of its lead drug formulations and achieving in-house commercial manufacturing capability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
-
Rhea-AI Summary
BioNxt Solutions Inc. (BNXT) settles $2,581,096 in convertible debentures and interest by issuing 162,192 common shares and an unsecured convertible debenture worth $2,500,000 to an arm's length creditor. Canaccord Genuity Corp. acted as the advisor and received 250,000 common shares and 250,000 common share purchase warrants for its services. Additionally, the company is in the process of issuing 604,000 finder's warrants to Canaccord in connection with a non-brokered private placement of common shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
Rhea-AI Summary
BioNxt Solutions Inc. (BNXT) settles $2,581,096 in convertible debentures and interest with an arm's length creditor by issuing common shares and an unsecured convertible debenture. The settlement terms include a conversion price of $0.50 per share, a maturity date of one year, and an 8% annual interest rate. Canaccord Genuity Corp. acted as the advisor in connection with the settlement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioNxt Solutions Inc. (BNXT) provides details on its clinical and commercialization strategy for its 100% Cladribine IP acquisition. The company is focusing on developing a proprietary oral dissolvable film (ODF) based Cladribine product for the treatment of Multiple Sclerosis (MS). Preclinical work is underway, and GMP product development and batch production are planned for 2024. The company aims to capitalize on the growing Cladribine tablet market, with potential advantages for an ODF product. The market for MS drugs is expected to reach over US$41 billion by 2033.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioNxt Solutions Inc. (BNXT) provides details on its 100% Cladribine IP acquisition and development program for a proprietary oral dissolvable film (ODF) based Cladribine product for the treatment of Multiple Sclerosis (MS). Cladribine, previously used for leukemia, has seen significant sales growth in the MS market. BioNxt's ODF formulation aims to offer advantages over conventional tablet forms, including instant dissolution and potential dosing precision. The company plans human bioequivalence studies for 2024 and has filed preliminary patent applications for Cladribine ODF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
BioNxt Solutions Inc. (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) signs a definitive agreement with a German-based pharmaceutical developer for the acquisition of 100% of the intellectual property rights and joint development of an oral dissolvable drug reformulation using the active pharmaceutical ingredient Cladribine. Cladribine is approved for use in over 75 countries for treating highly active forms of relapsing-remitting Multiple Sclerosis and certain forms of leukemia. The global Multiple Sclerosis drug market is expected to exceed US$ 41 Billion by 2033 according to Market.us. BioNxt aims to participate in this growing market with a proprietary dosage form based on its drug delivery platform, focusing on the Cladribine ODF and Rotigotine TDS development programs as priority initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
-
Rhea-AI Summary
BioNxt Solutions Inc. reports on a successful CPHI pharma conference in Barcelona, Spain. The conference had over 45,000 attendees and 1,500 exhibitors from over 150 countries. BioNxt's team was invited by major pharmaceutical companies to discuss projects related to its transdermal patch and oral dissolvable drug delivery platforms. Potential partners expressed interest in continued negotiations on potential cooperation terms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
BioNxt Solutions Inc. has closed the final tranche of its non-brokered private placement, raising $543,250 in gross proceeds. The total placement size was $2,000,750. The company plans to use the funds for research, development, and commercialization activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.95%
Tags
Rhea-AI Summary
BioNxt Solutions Inc. announces resignations of Per Thoresen and Peter Damouni as directors. Joseph Meagher appointed as a director to fill one vacancy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of BIONXT SOLUTIONS (BNXTF)?
The current stock price of BIONXT SOLUTIONS (BNXTF) is $0.29888 as of January 29, 2025.
What is the market cap of BIONXT SOLUTIONS (BNXTF)?
The market cap of BIONXT SOLUTIONS (BNXTF) is approximately 33.2M.
What does BioNxt Solutions Inc. specialize in?
BioNxt is a bioscience accelerator focused on next-gen drug formulations, delivery systems, and diagnostic tests for various medical applications.
What recent achievements has BioNxt Solutions Inc. made?
BioNxt has finalized a settlement agreement with a creditor, completed toxicity and pharmacokinetic studies for its Cladribine product, and launched a non-brokered private placement to fund research and development efforts.
What is the focus of BioNxt Solutions Inc.?
BioNxt is focused on regulatory approval and commercialization of medical products in European markets.
How is BioNxt Solutions Inc. positioned in the pharmaceutical industry?
BioNxt is at the forefront of developing innovative medical products and fostering collaboration in the pharmaceutical industry.
What sets BioNxt Solutions Inc. apart from other companies?
BioNxt's emphasis on innovation, collaboration, and cutting-edge research sets it apart in the pharmaceutical industry.
BIONXT SOLUTIONS INC
OTC:BNXTF
BNXTF Rankings
BNXTF Stock Data
33.16M
106.56M
6.03%
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Vancouver